Search company, investor...

Motif BioSciences



Total Raised


Date of IPO


Market Cap


About Motif BioSciences

Motif BioSciences is developing novel antibiotics designed to be effective against serious and life-threatening infections caused by multi-drug resistant bacteria. Motif has a lead antibiotic candidate, iclaprim, and MTF-001, a preclinical program to design a best-in-class dihydrofolate reductase inhibitor (DHFRi). Discussions and negotiations with academic institutes are under way to build a portfolio of antibiotic candidates through licensing. It is anticipated that Motif's lead antibiotic candidate could be ready for commercialization as early as 2018.

Headquarters Location

One Tudor Street

London, England, EC4Y 0AH,

United Kingdom

Missing: Motif BioSciences's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Motif BioSciences's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Motif BioSciences Patents

Motif BioSciences has filed 5 patents.

The 3 most popular patent topics include:

  • Antibiotics
  • Benzamides
  • Enantiopure drugs
patents chart

Application Date

Grant Date


Related Topics




Amines, Piperidines, Fluoroarenes, Piperazines, Carboxylic acids


Application Date


Grant Date



Related Topics

Amines, Piperidines, Fluoroarenes, Piperazines, Carboxylic acids



Latest Motif BioSciences News

Motif Bio : Corporate Update

Jan 28, 2020

Message : Corporate Update Reclassification as a Rule 15 Cash Shell Motif Bio plc (AIM/Nasdaq: MTFB) today provided an update on recent corporate developments following the General Meeting held on 14 November 2019 (the 'General Meeting'). Agreement with Hercules Capital, Inc The Company and its wholly owned subsidiary, Motif BioSciences Inc. ('Motif Inc'), have entered into a loan Amendment and Release agreement with Hercules Capital Inc. ('Hercules'), the senior secured lender to Motif Inc, regarding certain actions which fully satisfy the conditions attached to the Company's previously announced agreement in principle with Hercules (the 'Hercules Agreement'). Pursuant to the terms of the Hercules Agreement: Hercules is relinquishing the loan guarantee provided by the Company and relieving Motif Bio plc of any future obligations to Hercules related to the November 2017 Hercules Loan to Motif Inc (the 'Loan Agreement'). Motif Inc. has granted Hercules a perfected security interest in all of its intellectual property. To facilitate the wind down of Motif Inc. and potential sale of iclaprim related assets, Hercules has agreed with Motif Inc. to certain forbearance provisions under the Loan Agreement through to June 2020. The terms of the Hercules Agreement are effective immediately, except for provisions of a release that relate to the pledge of Motif Bio's interest in Motif Inc. which will become effective no later than 10 May 2020, being approximately 100 days after Hercules's security interest in all of the intellectual property of Motif Inc. is perfected, provided that no voluntary or involuntary bankruptcy filing has occurred with respect to Motif Bio or Motif Inc. Consistent with the resolutions passed at the General Meeting, the Company is granting to Hercules warrants over 24,267,408 ordinary shares and warrants over 97,069,633 ordinary shares which aggregate to 121,337,041 ordinary shares of 0.01 pence ('Ordinary Shares'), representing a total of 25 per cent of the Company's outstanding share capital (the 'Hercules Warrants'). The Hercules Warrants will expire on 27 January 2025 and have an exercise price of 0.42 pence, which is consistent with the placing price of the Company's Conditional Placing, which was announced on 2 October 2019. Motif Inc. has ceased all operations and has engaged Tamarack Associates to facilitate the sale of iclaprim and other assets of Motif Inc. In spite of a comprehensive outreach program, no transaction is currently pending for the sale of Motif Inc.'s assets and there is no assurance that there will be a transaction to monetise the assets. Consistent with the wind-down of operations of Motif Inc. and potential future sale of its assets, John Palmer of Tamarack Associates is being appointed as sole Executive Officer of Motif Inc. and Bernadette Barron of Barron Business Consultants is being appointed as the sole, independent non-executive officer of Motif Inc. Concurrent with these appointments, Graham Lumsden, Jonathan Gold, and David Huang have resigned as officers of Motif Inc. and Graham Lumsden has resigned as director of Motif Inc. Consistent with the information provided in the circular dated 25 October 2019, current directors have agreed to forfeit their outstanding vested and non-vested options. Graham Lumsden is voluntarily forfeiting 8,148,800 vested and non-vested options, Jonathan Gold is voluntarily forfeiting 1,330,941 vested and non-vested options, and Bruce Williams is voluntarily forfeiting 422,118 vested and non-vested options. Consistent with the information provided in the circular dated 25 October 2019, former directors Dr. Craig Albanese, Charlotta Ginman, Zaki Hosny, Dr. Mary Lake Polan, and Andrew Powell have forfeited their previously outstanding vested and non-vested options. In exchange for their forfeiture of their previously agreed Board fees, the Company is issuing to each of the above named former directors options over 1,200,000 ordinary shares at an exercise price of 0.24 pence (being the closing price on the date of execution of the Hercules agreement). Reclassification as a Rule 15 Cash Shell Following the execution of the Hercules Agreement, the Company will be reclassified as an AIM Rule 15 cash shell with immediate effect. As such, the Company will be required to make an acquisition which constitutes a reverse takeover under the AIM Rules within six months, failing which the Company's ordinary shares would be suspended from trading on AIM pursuant to AIM Rule 40. The Company's Directors are focused on sourcing an appropriate reverse takeover candidate for Motif Bio. There is no assurance that the effort will be successful to source and/or complete a reverse takeover transaction. The Company's Directors will provide shareholders with further updates as appropriate. Current Financial Position Motif Bio's cash balance was approximately £0.4 million as at 27 January 2020 and the Company currently has sufficient working capital to May 2020. As such, the Directors continue to impose disciplined cost controls and the Company is maintaining very limited operations. This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014. For further information please contact: Motif Bio plc Forward-Looking Statements When used in this Press Release, the words or phrases 'intends,' 'anticipates,' 'expected to be' or similar expressions are intended to identify 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to certain risks and uncertainties including, but not limited to, changes in economic conditions in the Company's market area, changes in policies by regulatory agencies, fluctuations in interest rates, competition that could cause actual results to differ materially from historical earnings and those presently anticipated or projected, and other risks described in the Company's filings with the Securities and Exchange Commission. The Company cautions readers not to place undue reliance on any such forward-looking statements, which speak only as of the date made. The Company advises readers that the factors listed above could affect the Company's financial performance and could cause the Company's actual results for future periods to differ materially from any opinions or statements expressed with respect to future periods in any current statements. The Company does not undertake, and specifically disclaims any obligation, to publicly release the result of any revision which may be made to any forward-looking statements to reflect events or circumstances after the date of such statements or to reflect the occurrence of anticipated or unanticipated events. Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014 1

Motif BioSciences Frequently Asked Questions (FAQ)

  • Where is Motif BioSciences's headquarters?

    Motif BioSciences's headquarters is located at One Tudor Street, London.

  • What is Motif BioSciences's latest funding round?

    Motif BioSciences's latest funding round is IPO.

  • How much did Motif BioSciences raise?

    Motif BioSciences raised a total of $2.88M.

  • Who are the investors of Motif BioSciences?

    Investors of Motif BioSciences include Amphion Innovations PLC. and Acceleration International.

  • Who are Motif BioSciences's competitors?

    Competitors of Motif BioSciences include Nuclea Biotechnologies, Galenea, NewLink Genetics, Inspire Pharmaceuticals, PregLem and 13 more.

Compare Motif BioSciences to Competitors


Idiomics, LLC is a biotechnology company providing health providers, healthcare payors and pharmaceutical companies informatics and biotechnology tools and platforms to personalize medical care to the individual patient.

Genaissance Pharmaceuticals

Personalized medicine through population genomics and informatics.

Bauer BioMedical

Bauer BioMedical, LLC is at the forefront of technological advances in the field of Genetic Translational Medicine. The company is in the process of finding applications for the company's Intellectual Property in the fields of Preemptive Medicine and Theranostics.

MODA Technology Partners

MODA Technology Partners is a provider of informatics solutions for pharmaceutical and biotechnology quality manufacturing

EGeen International Logo
EGeen International

EGeen International is a privately held emerging biotechnology company focused on drug and diagnostic target discovery, and personalized medicine applications. EGeen has exclusive commercial rights to the information from the Estonian Genome Project, a major national effort in Estonia with the objective of gathering medical information and blood samples from consented population. The Company will continue to establish biopharmaceutical and pharmacogenetic collaborations with partners seeking to validate drug target candidates and genetic drug profiles. More information about the Company can be found at

Argolyn Bioscience

Argolyn Bioscience is a privately held biopharmaceutical company dedicated to discovering and developing novel peptide drug candidates to treat psychosis, pain, and other serious diseases and disorders. Its most advanced development candidate is ABS201, a first-in-class peptide derivative currently in preclinical development for the treatment of schizophrenia.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.